The FDA Just Changed the Rules on Coverage - What Early-Stage Companies Need to Know.

On April 23, 2026, the FDA and CMS announced the RAPID coverage pathway - a new program designed to cut the historically long gap between FDA device authorization and Medicare coverage from a year or more down to as little as two months. For early-stage life science device companies, this changes the commercial math.

In this episode, we break down exactly what RAPID is, who qualifies, what it means for your launch strategy, and five specific steps you should be taking right now.

1. Determine your eligibility right now. If you have or are pursuing Breakthrough Device designation for a Class II or Class III device with a significant Medicare-age patient population, RAPID may apply to you.
2. Audit your IDE study design immediately. The RAPID pathway requires that your clinical outcomes be agreed upon by both FDA and CMS in advance. If your current study design was built solely around FDA's evidentiary requirements, you may have a gap.
3. Request a CMS engagement meeting. CMS has committed to early and frequent engagement with RAPID-eligible device companies during development. That is not a formality - it is a strategic resource built into the pathway.
4. Update your commercial launch model. If you have been modeling a one-to-two year gap between FDA authorization and Medicare coverage, and RAPID applies to your device, your timeline assumptions are out of date.
5. Engage the public comment process. When the RAPID proposed procedural notice hits the Federal Register, you will have 60 days to submit comments.

Sources Referenced in This Episode:

• CMS.gov - RAPID Coverage Pathway Press Release, April 23, 2026
• FDA.gov - Joint CMS/FDA Announcement, April 23, 2026
• Foley Hoag LLP - RAPID Pathway Legal Analysis, April 2026
• Healthcare Dive - 'CMS, FDA unveil speedier Medicare coverage pathway,' April 23, 2026
• STAT News - 'CMS, FDA propose new, faster coverage for breakthrough devices,' April 23, 2026
• Arnold & Porter - Regulatory & Reimbursement Analysis, April 2026

 

About Life Science Logic:

Life Science Logic is a commercial strategy consultancy serving small life science, healthcare companies, and healthcare investors. We help founders and operators navigate go-to-market strategy, competitive intelligence, and commercial planning with the clarity and rigor that early-stage companies deserve and need. Learn more at lifesciencelogic.com or reach me at Eric@lifesciencelogic.com.

CONNECT

• Website: https://lifesciencelogic.com/
• Email: Eric@lifesciencelogic.com